Paul J Catalano

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2924612/publications.pdf

Version: 2024-02-01

64 papers

3,135 citations

236925 25 h-index 52 g-index

64 all docs 64
docs citations

64 times ranked 5300 citing authors

#	Article	IF	CITATIONS
1	Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma. Nature Medicine, 2020, 26, 909-918.	30.7	488
2	Incidence and prognosis of patients with brain metastases at diagnosis of systemic malignancy: a population-based study. Neuro-Oncology, 2017, 19, 1511-1521.	1.2	483
3	Brain Metastases in Newly Diagnosed Breast Cancer. JAMA Oncology, 2017, 3, 1069.	7.1	224
4	Impact of the New U.S. Department of Agriculture School Meal Standards on Food Selection, Consumption, and Waste. American Journal of Preventive Medicine, 2014, 46, 388-394.	3.0	198
5	Incidence and Demographic Burden of HPV-Associated Oropharyngeal Head and Neck Cancers in the United States. Cancer Epidemiology Biomarkers and Prevention, 2019, 28, 1660-1667.	2.5	127
6	Effects of Choice Architecture and Chef-Enhanced Meals on the Selection and Consumption of Healthier School Foods. JAMA Pediatrics, 2015, 169, 431.	6.2	97
7	Prognostic importance of human papillomavirus (HPV) and p16 positivity in squamous cell carcinoma of the vulva treated with radiotherapy. Gynecologic Oncology, 2016, 142, 293-298.	1.4	87
8	Ipilmumab and cranial radiation in metastatic melanoma patients: a case series and review., 2015, 3, 50.		84
9	Adjuvant radiation therapy, local recurrence, and the need for salvage therapy in atypical meningioma. Neuro-Oncology, 2014, 16, 1547-1553.	1.2	80
10	irRECIST for the Evaluation of Candidate Biomarkers of Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma: Analysis of a Phase II Prospective Clinical Trial. Clinical Cancer Research, 2019, 25, 2174-2184.	7.0	80
11	Representativeness of Participants in the Cancer Care Outcomes Research and Surveillance Consortium Relative to the Surveillance, Epidemiology, and End Results Program. Medical Care, 2013, 51, e9-e15.	2.4	78
12	Outcomes by Tumor Histology and KRAS Mutation Status After Lung Stereotactic BodyÂRadiation Therapy for Early-Stage Non–Small-Cell Lung Cancer. Clinical Lung Cancer, 2015, 16, 24-32.	2.6	67
13	The need for preoperative baseline arm measurement to accurately quantify breast cancer-related lymphedema. Breast Cancer Research and Treatment, 2016, 157, 229-240.	2.5	60
14	Changing prognostic significance of tumor stage and nodal stage in patients with squamous cell carcinoma of the oropharynx in the human papillomavirus era. Cancer, 2015, 121, 2594-2602.	4.1	53
15	Prospective assessment of deep inspiration breath-hold using 3-dimensional surface tracking for irradiation of left-sided breast cancer. Practical Radiation Oncology, 2015, 5, 358-365.	2.1	49
16	Expression of T-Cell Exhaustion Molecules and Human Endogenous Retroviruses as Predictive Biomarkers for Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma. Clinical Cancer Research, 2021, 27, 1371-1380.	7.0	49
17	Percutaneous Imaging-Guided Cryoablation of Liver Tumors: Predicting Local Progression on 24-Hour MRI. American Journal of Roentgenology, 2014, 203, W181-W191.	2.2	45
18	Outcomes with image-based interstitial brachytherapy for vaginal cancer. Radiotherapy and Oncology, 2016, 120, 486-492.	0.6	42

#	Article	IF	CITATIONS
19	Percutaneous treatment of hepatocellular carcinoma in patients with cirrhosis: A comparison of the safety of cryoablation and radiofrequency ablation. European Journal of Radiology, 2014, 83, 632-638.	2.6	40
20	Rates and Durability of Response to Salvage Radiation Therapy Among Patients With Refractory or Relapsed Aggressive Non-Hodgkin Lymphoma. International Journal of Radiation Oncology Biology Physics, 2015, 91, 223-231.	0.8	40
21	Phase II Study of Nivolumab and Salvage Nivolumab/Ipilimumab in Treatment-Naive Patients With Advanced Clear Cell Renal Cell Carcinoma (HCRN GU16-260-Cohort A). Journal of Clinical Oncology, 2022, 40, 2913-2923.	1.6	40
22	MR- versus CT-based high-dose-rate interstitial brachytherapy for vaginal recurrence of endometrial cancer. Brachytherapy, 2017, 16, 1159-1168.	0.5	32
23	Few Changes in Food Security and Dietary Intake From Short-term Participation in the Supplemental Nutrition Assistance Program Among Low-income Massachusetts Adults. Journal of Nutrition Education and Behavior, 2014, 46, 68-74.	0.7	31
24	Cabozantinib in Patients with Advanced Merkel Cell Carcinoma. Oncologist, 2018, 23, 814-821.	3.7	30
25	ACE2 abrogates tumor resistance to VEGFR inhibitors suggesting angiotensin-(1-7) as a therapy for clear cell renal cell carcinoma. Science Translational Medicine, $2021, 13, .$	12.4	29
26	Healthier Standards for School Meals and Snacks. American Journal of Preventive Medicine, 2016, 51, 485-492.	3.0	28
27	Body Mass Index and Locoregional Recurrence in Women with Early-Stage Breast Cancer. Annals of Surgical Oncology, 2016, 23, 3870-3879.	1.5	28
28	Racial disparities in supportive medication use among older patients with brain metastases: a population-based analysis. Neuro-Oncology, 2020, 22, 1339-1347.	1.2	27
29	The risk of lymphedema after postoperative radiation therapy in endometrial cancer. Journal of Gynecologic Oncology, 2016, 27, e4.	2.2	25
30	Population-based estimates of survival among elderly patients with brain metastases. Neuro-Oncology, 2021, 23, 661-676.	1.2	25
31	Evaluating the PD-1 Axis and Immune Effector Cell Infiltration in Oropharyngeal Squamous Cell Carcinoma. International Journal of Radiation Oncology Biology Physics, 2018, 102, 137-145.	0.8	24
32	Dosimetric Inhomogeneity Predicts for Long-Term Breast Pain After Breast-Conserving Therapy. International Journal of Radiation Oncology Biology Physics, 2015, 93, 1087-1095.	0.8	21
33	Patterns of failure after reirradiation with intensity-modulated radiation therapy and the competing risk of out-of-field recurrences. Oral Oncology, 2016, 61, 19-26.	1.5	20
34	Impact of pemetrexed on intracranial disease control and radiation necrosis in patients with brain metastases from non-small cell lung cancer receiving stereotactic radiation. Radiotherapy and Oncology, 2018, 126, 511-518.	0.6	18
35	Hepatic Microwave Ablation Zone Size: Correlation with Total Energy, Net Energy, and Manufacturer-Provided Chart Predictions. Journal of Vascular and Interventional Radiology, 2016, 27, 1389-1396.	0.5	17
36	Neurosurgical Resection and Stereotactic Radiation Versus Stereotactic Radiation Alone in Patients with a Single or Solitary Brain Metastasis. World Neurosurgery, 2019, 122, e1557-e1561.	1.3	17

#	Article	IF	Citations
37	Eastern Cooperative Oncology Group and American College of Radiology Imaging Network Randomized Phase 2 Trial of Neoadjuvant Preoperative Paclitaxel/Cisplatin/Radiation Therapy (RT) or Irinotecan/Cisplatin/RT in Esophageal Adenocarcinoma: Long-Term Outcome and Implications for Trial Design. International Journal of Radiation Oncology Biology Physics, 2016, 94, 738-746.	0.8	16
38	The Intensive Palliative Care Unit: Changing Outcomes for Hospitalized Cancer Patients in an Academic Medical Center. Journal of Palliative Medicine, 2017, 20, 285-289.	1.1	15
39	Master Protocol Trial Design for Efficient and Rational Evaluation of Novel Therapeutic Oncology Devices. Journal of the National Cancer Institute, 2020, 112, 229-237.	6.3	15
40	Assessing ablation margins of FDG-avid liver tumors during PET/CT-guided thermal ablation procedures: a retrospective study. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2914-2924.	6.4	14
41	Validation and Application of the Mass Balance Model To Determine the Effectiveness of Portable Air Purifiers in Removing Ultrafine and Submicrometer Particles in an Apartment. Environmental Science & Technology, 2015, 49, 9592-9599.	10.0	13
42	Outcomes with volume-based dose specification in CT-planned high-dose-rate brachytherapy for stage I-II cervical carcinoma: A 10-year institutional experience. Gynecologic Oncology, 2016, 143, 545-551.	1.4	13
43	Local control after brain-directed radiation in patients with cystic versus solid brain metastases. Journal of Neuro-Oncology, 2019, 142, 355-363.	2.9	13
44	Arterial Spin Labeled Perfusion MRI for the Evaluation of Response to Tyrosine Kinase Inhibition Therapy in Metastatic Renal Cell Carcinoma. Radiology, 2021, 298, 332-340.	7.3	13
45	Utility of claims data for identification of date of diagnosis of brain metastases. Neuro-Oncology, 2020, 22, 575-576.	1.2	12
46	Seizures Among Patients With Brain Metastases. Neurology, 2021, 96, .	1.1	12
47	Radiation toxicity in patients with collagen vascular disease and intrathoracic malignancy treated with modern radiation techniques. Radiotherapy and Oncology, 2017, 125, 301-309.	0.6	11
48	Variation in National Use of Long-Term ADT by Disease Aggressiveness Among Men With Unfavorable-Risk Prostate Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2016, 14, 421-428.	4.9	10
49	Comparison of performance of various tumor response criteria in assessment of sunitinib activity in advanced gastrointestinal stromal tumors. Clinical Imaging, 2016, 40, 880-884.	1.5	9
50	Funding Support and Principal Investigator Leadership of Oncology Clinical Trials Using Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2018, 102, 34-43.	0.8	9
51	Local Therapies for Brain Metastases, Competing Risks, and Overall Survival. International Journal of Radiation Oncology Biology Physics, 2015, 91, 718-720.	0.8	8
52	A Phase 1 Study of Afatinib in Combination with Postoperative Radiation Therapy with and Without Weekly Docetaxel in Intermediate- and High-Risk Patients with Resected Squamous Cell Carcinoma of the Head and Neck. International Journal of Radiation Oncology Biology Physics, 2019, 105, 132-139.	0.8	8
53	Doxorubicin and subsequent risk of cardiovascular diseases among survivors of diffuse large B-cell lymphoma in Hong Kong. Blood Advances, 2020, 4, 5107-5117.	5.2	8
54	F-18 FDG perfusion PET: intraprocedural assessment of the liver tumor ablation margin. Abdominal Radiology, 2021, 46, 3437-3447.	2.1	8

#	Article	IF	CITATIONS
55	Rectal bleeding after radiation therapy for endometrial cancer. Radiotherapy and Oncology, 2015, 115, 240-245.	0.6	7
56	Patient-oriented toxicity endpoints after head and neck reirradiation with intensity modulated radiation therapy. Oral Oncology, 2017, 73, 160-165.	1.5	7
57	Effects of Postmastectomy Radiation Therapy on Immediate Tissue Expander and Acellular Dermal Matrix Reconstruction: Results of a Prospective Clinical Trial. Practical Radiation Oncology, 2019, 9, 338-346.	2.1	7
58	Prescription of memantine during non-stereotactic, brain-directed radiation among patients with brain metastases: a population-based study. Journal of Neuro-Oncology, 2020, 148, 509-517.	2.9	7
59	Outcomes by EGFR, KRAS, and ALK Genotype After Combined Modality Therapy for Locally Advanced Non–Small-Cell Lung Cancer. JCO Precision Oncology, 2018, 2, 1-18.	3.0	5
60	Comprehensive Genomic Profiling of Metastatic Tumors in a Phase 2 Biomarker Study of Everolimus in Advanced Renal Cell Carcinoma. Clinical Genitourinary Cancer, 2018, 16, 341-348.	1.9	5
61	Utility of claims data for delineation of intracranial treatment among patients with brain metastases. Neuro-Oncology, 2020, 22, 1547-1548.	1.2	2
62	Lung Cancer Strategist Program: A novel care delivery model to improve timeliness of diagnosis and treatment in high-risk patients. Healthcare, 2021, 9, 100563.	1.3	2
63	Incidence and Predictors of Neurologic Death in Patients with Brain Metastases. World Neurosurgery, 2022, 162, e401-e415.	1.3	2
64	Emergency department visits and inpatient hospitalizations among older patients with brain metastases: a dual population- and institution-level analysis. Neuro-Oncology Practice, 2021, 8, 569-580.	1.6	1